Epizyme is financed by blue chip financial and strategic investors, including Kleiner Perkins Caufield & Byers, MPM Capital, Bay City Capital, New Enterprise Associates, Astellas Ventures and Amgen Ventures.  The expertise and financial scale of these investors position Epizyme as the leading company translating breakthroughs in the field of epigenetics into a new class of drugs.